The quarter missed the available earnings bar. Kodiak reported a $1.05 per-share loss versus published estimates clustered around roughly $0.96–$0.97, making the result modestly worse than expected.
| Metric | Q2 2026 | Q2 2025 / reference |
|---|---|---|
| Net loss | $65.6 million | $54.3 million (Net loss) |
| Loss per share | $1.05 | $1.03 (Condensed Statements of Operations) |
| R&D expense | $56.1 million | $42.8 million (R&D Expenses) |
| G&A expense | $10.8 million | $12.8 million (G&A Expenses) |
| Cash and equivalents | $125.9 million | $209.9 million at Dec. 31, 2025 (Balance Sheet Data) |
The higher loss reflects spending behind the pipeline, not a new commercial setback. R&D rose about 31% year over year as PEAK/PINNACLE clinical work and Phase 3 manufacturing accelerated, while G&A declined. That is understandable for a pre-commercial biotech, but it still means the company is consuming cash faster while revenue remains absent. (R&D Expenses; Condensed Statements of Operations)
The meaningful operating update was broadly on schedule rather than ahead of it. Kodiak completed enrollment in the first 300-patient PEAK cohort, began enrolling the roughly 910-patient ALTO study, and maintained September 2026 DAYBREAK data and December 2026 PEAK data timing. Those are constructive execution markers, but the readout calendar was already the central near-term expectation; the filing mostly confirms it rather than creating a fresh surprise. (Recent Business Highlights)
Net read: an earnings miss with the clinical setup intact. The $125.9 million cash balance is stated to support planned operations into 2027, but the filing does not add financing or extend that runway beyond the prior framing. With the next value-defining event still the September DAYBREAK topline readout, the financial result lands slightly below expectations while the clinical narrative remains broadly in line. (Cash Position; Phase 3 DAYBREAK Study)
Read the original 8-K on SEC EDGAR ↗